Taysha Gene Therapies (TSHA) Free Cash Flow (2020 - 2026)

Taysha Gene Therapies has reported Free Cash Flow for 7 years, with the latest figure at -$40.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 85.56% year-over-year to -$40.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$112.7 million (down 34.63% YoY) and the FY2025 annual result came in at -$93.8 million, down 14.99% from the prior year.
• Free Cash Flow slipped to -$40.9 million in Q1 2026 per TSHA's latest filing, from -$27.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$5.9 million in Q4 2022 and troughed at -$41.0 million in Q1 2022.
• A 5-year average of -$23.7 million and a median of -$21.8 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2022 and 2023: Free Cash Flow jumped 87.91% in 2022, then sank 233.44% in 2023.
• Over 5 years, Free Cash Flow stood at -$5.9 million in 2022, then tumbled by 233.44% to -$19.6 million in 2023, then climbed by 6.43% to -$18.3 million in 2024, then slumped by 49.87% to -$27.4 million in 2025, then slumped by 49.09% to -$40.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$40.9 million, -$27.4 million, and -$23.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.